Adipose-Derived Stem Cell Eye Drops for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for canine dry eye syndrome, particularly those involving immunosuppressive eye drops, have limited therapeutic effects and require frequent administration, posing challenges for patient compliance and effectiveness.
Innovation Solution
The use of adipose-derived mesenchymal stem cells (Ad-MSC) in the form of topical eye drops, which are administered once a week for six consecutive weeks, providing an immunomodulatory effect to enhance tear fluid secretion and improve ocular surface health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunosuppressive eye drops are used to treat dry eye syndrome, then therapeutic effect is achieved, but frequent administration is required which reduces patient compliance
Solution Approach 1:
The patent transforms continuous frequent administration into periodic weekly administration. Ad-MSCs are administered once a week for six consecutive weeks, creating a periodic treatment schedule that maintains therapeutic effectiveness while dramatically improving patient compliance by reducing administration frequency from multiple times daily to once weekly.
Solution Approach 2:
The patent enables the treatment system to sustain its own therapeutic effect without continuous external intervention. Ad-MSCs implant themselves in the ocular surface and continuously secrete immunomodulatory factors, creating a self-sustaining therapeutic system that reduces dependency on frequent external administrations.
2Reliability
If traditional immunosuppressive eye drops are used, then treatment is provided, but therapeutic effect is limited and does not work for all patients
Solution Approach 1:
The patent changes the fundamental parameter of treatment from chemical immunosuppression to cellular immunomodulation. By using Ad-MSCs instead of chemical immunosuppressive agents, the treatment achieves broader adaptability and effectiveness across different patient populations, including those who do not respond to traditional immunosuppressants.
3Reliability
If frequent administration of eye drops is required, then continuous therapeutic coverage is maintained, but patient comfort and quality of life are reduced
Solution Approach 1:
The patent performs preliminary action by administering Ad-MSCs that implant and establish themselves in the ocular surface before continuous therapeutic coverage is needed. This preliminary cellular implantation creates a foundation for sustained immunomodulation, eliminating the need for frequent subsequent administrations and improving patient comfort.
Data Source
AI summary
The present invention provides a method of treating a subject suffering from dry eye syndrome, comprising: administering to said subject a pharmaceutical composition for treating dry eye syndrome, comprising an effective amount of adipose-derived mesenchymal stem cells and the pharmaceutical composition is administered to the eye topically in the form of eye drops.